Back to Search
Start Over
Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
- Source :
- The Journal of Clinical Hypertension, Vol 24, Iss 4, Pp 449-456 (2022)
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- Abstract Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). The authors aimed to study whether it can be used as an antihypertensive agent in patients with refractory hypertension who have already been treated. A total of 66 Chinese patients with refractory hypertension were enrolled. Patients received sacubitril/valsartan 200 instead of angiotensin II receptor blocker or angiotensin converting enzyme inhibitor while other agents continued. If BP was uncontrolled after 4 weeks, sacubitril/valsartan was increased to 400 mg. The BP reduction was evaluated by office BP and ambulatory BP monitoring after 8‐week treatment. The baseline office BP and mean arterial pressure (MAP) were 150.0/95.0 mmHg and 113.3 mmHg. BP and MAP reduced to 130.6/83.2 mmHg and 99.0 mmHg at week 8. Office BP and MAP reductions were 19.4/11.8 mmHg and 14.3 mmHg at endpoint (all p
Details
- Language :
- English
- ISSN :
- 17517176 and 15246175
- Volume :
- 24
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- The Journal of Clinical Hypertension
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0f542cdc843488ba306c125aed68119
- Document Type :
- article
- Full Text :
- https://doi.org/10.1111/jch.14454